Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Animal cell – per se – expressing immunoglobulin – antibody – or...
Reexamination Certificate
2002-01-02
2008-05-13
Rawlings, Stephen L. (Department: 1643)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Animal cell, per se, expressing immunoglobulin, antibody, or...
C530S350000, C530S388220
Reexamination Certificate
active
07371574
ABSTRACT:
The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VIE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine ceH indicated that E4B9 indeed cross-reacts with human VE-cadherin (FIG.6). This finding facilitates development of a “humanized” E4B9 antibody and its success in the prectinical development since its anti-tumor activity can be tested extensively in several mouse models.
REFERENCES:
patent: 5597725 (1997-01-01), Suzuki
patent: 5646250 (1997-07-01), Suzuki
patent: 2003/0206902 (2003-11-01), Liao et al.
patent: 2005/0222037 (2005-10-01), Blaschuk et al.
patent: WO 99/57149 (1999-11-01), None
Corada et al. Blood, vol. 97, No. 6, Mar. 2001.
Greenspan et al. Nature Biotechnology 7:936-937 1999.
Database IMSDRUGNEWS (R & D Focus Drug News, Nov. 17, 1997).
Skolnick et al. (Trends Biotechnol. 2000; 18 (1): 34-39).
Bowie et al. (Science 1990; 257: 1306-1310).
Burgess et al. (Journal of Cell Biology 1990; 111: 2129-2138).
Lazar et al. (Molecular and Cellular Biology, 1988, 8: 1247-1252).
Luque et al. (Biochem. Nov. 19, 2002; 41 (46): 13663-13671).
Vucic et al. (J. Biol. Chem. Dec. 18, 1998; 273 (51): 33915-33921).
Takada et al. (Mol. Endocrinol. 2000; 14 (5): 733-740).
Guo et al. (Proc. Natl. Acad. Sci. USA. Jun. 22, 2004; 101 (25): 9205-9210).
Gura (Science. 1997; 278: 1041-1042).
Saijo et al. (Cancer Sci. Oct. 2004; 95 (10): 772-776).
Kelland (Eur. J. Cancer. Apr. 2004; 40 (6): 827-836).
Schuh (Toxicologic Pathology. 2004; 32 (Suppl. 1): 53-66).
Bibby (Eur. J. Cancer. Apr. 2004; 40 (6): 852-857).
Peterson et al. (Eur. J. Cancer. 2004; 40: 837-844).
Dennis (Nature. Aug. 7, 2006; 442: 739-741).
Navarro et al. (J. Cell Biol. Mar. 23, 1998; 140 (6): 1475-1484).
Lampugnani et al. (J. Cell. Biol. 1992; 118: 1511-1522).
Yang et al. (Am. J. Pathol. Sep. 1999; 155 (3): 887-895).
Bach et al. (J. Biol. Chem. Nov. 13, 1998; 273 (46): 30719-30728).
May et al. (Blood. Jun. 1, 2005; 105 (11): 4337-4344).
Liao et al. (Cancer Res. Dec. 15, 2000; 60: 6805-6810).
Corada et al. (Blood. Aug. 1, 2002; 100 (3): 905-911).
Carmeliet et al., “Targeted Deficiency or Cytosolic Truncation of the VE-cadherin Gene in Mice Impairs VEGF-Mediated Endothelial Survival and Angiogenesis,” Cell, vol. 98, Jul. 23, 1999, pp. 147-157.
Vittet et al., “Targeted Null-mutation in the Vascular Endothelial-Cadherin Gene Impairs the Organization of Vascular-like Structures in Embryoid Bodies,” Proc. Natl. Acad. Sci. USA, vol. 94, Jun. 1997, pp. 6273-6278.
Caveda et al., “Inhibition of Cultured Cell Growth by Vascular Endothelial Cadherin (Cadherin-5/VE-Cadherin),” J. Clin. Invest., vol. 98, No. 4, Aug. 1996, pp. 886-893.
Corada et al., “Vascular Endothelial-cadherin is an Important Determinant of Microvascular Integrity In Vivo,” Proc. Natl. Acad. Sci. USA, vol. 96, Aug. 1999, pp. 9815-9820.
Uemura et al., “The Cadherin Superfamily at the Synapse: More Members, More Missions,” Cell, vol. 93, Jun. 26, 1998, pp. 1095-1098.
Bach et al., “VE-Cadherin Mediates Endothelial Cell Capillary Tube Formation in Fibrin and Collagen Gels,” Experimental Cell Research, vol. 238, No. 2, 1998, pp. 324-334.
Breier et al., “Molecular Cloning and Expression of Murine Vascular Endothelial-Cadherin in Early Stage Development of Cardiovascular System,” Blood, vol. 87, No. 2, Jan. 15, 1996, pp. 630-641.
Maschio et al., “Polymorphonuclear Leukocyte Adhesion Triggers the Disorganization of Endothelial Cell-to-Cell Adherens Junctions,” The Journal of Cell Biology, vol. 135, No. 2, Oct. 1996, pp. 497-510.
Martin-Padura et al., “Functional Adhesion Molecule, a Novel Member of the Immunoglobulin Superfamily that Distributes at Intercellular Junctions and Modulates Monocyte Transmigration,” The Journal of Cell Biology, vol. 142, No. 1, Jul. 13, 1998, pp. 117-127.
Liao et al., “Identification of antibody-based VE-cadherin antagonists for the application of anti-angiogenesis therapy,” Proc. Nat'l Acad. Sci. USA, vol. 41, Mar. 2000, abstract #4096.
Breviario et al., “Functional properties of human vascular endothelial cadherin (7B4/cadherin-5), and endothelium-specific cadherin,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 15, No. 8, Aug. 1995, pp. 1229-1239.
Haselton et al., “Role of cadherins 5 and 13 in the aortic endothelial barrier,” Journal of Cellular Physiology, vol. 171, No. 3, Jun. 1997, pp. 243-251.
Corada et al., “Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability,” Blood, vol. 97, No. 6, Mar. 15, 2001, pp. 1679-1684.
Takeichi, Ann. Rev. Biochem. (1990), 59:237-252.
Geiger & Ayalon, Ann. Rev. Cell Biol. (1992), 8:302-332.
Nose et al., Cell (1988), 54:993-1001.
Shapiro et al., Nature (1996), 374:327-337.
Lampugnani et al., J. Cell. Biol. (1992), 118:1511-1522.
Rabiet et al., Arterioscler. Thromb. Vasc. Biol. (1996), 16:488-496.
Dejana, J. Clin. Invest. (1997), 100:S7-10.
Dejana et al., Faseb J. (1995), 9:910-918.
Dejana et al., Ann NY Acad Sci. (1997), 811:36-43.
Kevil et al., J. Biol. Chem. (1988) 273:15099-15103.
Yap et al., J. Cell Biol. (1998), 141:779-789.
Faure et al., Development (1999), 128: 2093-2101.
Ali et al., Microcirculation 4:267-277 (1997).
Berman et al., EMBO J. 7:727-738 (1988).
Bowie et al., Science, 247:1306-1310 (1990).
Burgess et al., J. of Cell Bio. 111:2129-2138 (1990).
Cole, et al., 1985, In Moloclonal Antibodies and Cancer therapy, Alan R. Liss, Inc., pp. 77-96.
Gillman & Smith, Gene 8:81-97 (1979).
Gotsch et al., J. Cell Sci. 110:583-588 (1997).
Gumbiner, B., & Simons, K., Cell Biol. 102:457-468 (1996).
Kohler & Milstein, Nature, 256:495-497 (1975).
Kozbor et al., Immunology Today 4:72, (1983).
Lampugnani et al., J. Cell Biol. 129:203-217 (1995).
Lazar et al., Molecular and Cellular Biology 8:1247-1252 (1988).
Nagar et al., Nature 380:360-364 (1996).
Overduin et al., Science 267:386-389 (1995).
Queen, Nature 351:501 (1991).
Roberts, et al., Nature 328:731-734 (1987).
Piggot et al. (1991) Structural and Functional Studies of the Endothelial Activation Antigen Endothelial Leucocyte Adhesion Molecule-1 . . . , J. Immun. 147(1): 130-135.
Bohlen Peter
Hicklin Daniel J.
Liao Fang
Imclone Systems Inc.
Lucas & Mercanti LLP
Rawlings Stephen L.
LandOfFree
Antibody antagonists of VE-cadherin without adverse effects... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody antagonists of VE-cadherin without adverse effects..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody antagonists of VE-cadherin without adverse effects... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3985537